Immune-boosting antibody combination could improve lymphoma survival

Anne Li                                                                                     December 12th, 2017


Combining two different immunotherapy treatments could dramatically improve lymphoma survival, according to a Cancer Research UK funded study published in Cancer Cell. Researchers from the University of Southampton tested different combinations of antibodies in the lab to see how they interact with each other and what effect this has on how the immune system fights cancer. They found one combination – anti-CD27 and anti-CD20 – greatly increased life expectancy in mice with cancer. While most of the mice given just one of the antibodies died within 80 days, nearly all mice given both antibodies survived beyond 100 days.


See original article at: http://www.cancerresearchuk.org/about-us/cancer-news/press-release/2017-11-30-immune-boosting-antibody-combination-could-improve-lymphoma-survival

Post a comment